Thoracic Oncology Group of Australasia

News

Get the latest news, treatments, ASM highlights and topics in lung cancer and mesothelioma from The Thoracic Oncology Group of Australasia (TOGA).

Post Category Filter Radio Buttons
This meeting provided a full slate with 9 concepts submitted. The concepts spanned the interest areas of every working group and we thank those who
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
We are pleased to announce some exciting changes to the TOGA Board of Directors.
Experience Kosi with Nick Pavlakis and the TOGA team to help fundraise for lung cancer research.
ALK Positive Australia Inc. and the Thoracic Oncology Group of Australia (TOGA) are honoured to announce a new grant partnership dedicated to advancing ALK+ NSCLC
October 13, 2024
On October 13, take part in the 2024 Nike Marathon Festival to run/walk the iconic route and finish in the MCG. Don’t miss out on
We are pleased to announce some exciting changes to the TOGA Board of Directors.
We’ve all seen the exciting ‘practice-changing’ results presented at conferences like ESMO 2023. But how do these new cancer treatments become available for everyday use
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
We’ve all seen the exciting ‘practice-changing’ results presented at conferences like ESMO 2023. But how do these new cancer treatments become available for everyday use
August 11, 2024
Join the team to run or walk Sydney’s iconic 14km course from the CBD to Bondi Beach on Sunday 11 August 2024.
Angeline Low wasn't your typical candidate for lung cancer. A busy corporate leader with a Ph.D., and an active member of various boards, Angeline embodied
Lung cancer remains a leading cause of death, and nurses specialising in this area play a critical role in patient care. However, securing funding for
This meeting provided a full slate with 9 concepts submitted. The concepts spanned the interest areas of every working group and we thank those who
Last week brought fantastic news for the fight against lung cancer. The Australian Government announced a record-breaking $1.89 billion investment in health and medical research,
Have you been diagnosed with lung cancer and are overwhelmed by treatment options?
Imagine a world where medical research doesn’t have to start from scratch. Imagine a treasure trove of valuable data readily available to answer new questions
OCEANiC is a phase II multi-centre clinical trial targeting patients with resected stage II to IIIA EGFR mutant NSCLC. The trial provides access to Osimertinib
Facing a diagnosis can be a daunting journey, rife with uncertainty and difficult decisions. Among these decisions is the choice of whether to participate in
Three compelling reasons why becoming a participant in cancer clinical trials is not only a noble endeavor but also a decision that can hold profound
August 13, 2023
Congratulations to all the participants of City2Surf 2023 who successfully completed the challenging 14km course among a massive field of 80,000 competitors.
The 2023 Annual Scientific Meeting showcased the latest lung cancer research highlighting the importance of a multidisciplinary approach.
On May 2, 2023, the Australian Government announced a significant investment of $263.8 million over four years to establish the national Lung Cancer Screening Program
Recommendation by the Medical Services Advisory Committee (MSAC).
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or